155 related articles for article (PubMed ID: 15623606)
1. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.
Takebe N; Cheng X; Wu S; Bauer K; Goloubeva OG; Fenton RG; Heyman M; Rapoport AP; Badros A; Shaughnessy J; Ross D; Meisenberg B; Tricot G
Clin Cancer Res; 2004 Dec; 10(24):8301-8. PubMed ID: 15623606
[TBL] [Abstract][Full Text] [Related]
2. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients.
Weigel G; Griesmacher A; Zuckermann AO; Laufer G; Mueller MM
Clin Pharmacol Ther; 2001 Mar; 69(3):137-44. PubMed ID: 11240978
[TBL] [Abstract][Full Text] [Related]
3. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic monitoring of mycophenolate mofetil.
Budde K; Glander P; Bauer S; Braun K; Waiser J; Fritsche L; Mai I; Roots I; Neumayer HH
Clin Chem Lab Med; 2000 Nov; 38(11):1213-6. PubMed ID: 11156363
[TBL] [Abstract][Full Text] [Related]
5. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells.
Takebe N; Cheng X; Fandy TE; Srivastava RK; Wu S; Shankar S; Bauer K; Shaughnessy J; Tricot G
Mol Cancer Ther; 2006 Feb; 5(2):457-66. PubMed ID: 16505121
[TBL] [Abstract][Full Text] [Related]
6. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.
Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M
Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
[TBL] [Abstract][Full Text] [Related]
8. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil: a dermatologic perspective.
Mydlarski PR
Skin Therapy Lett; 2005 Apr; 10(3):1-6. PubMed ID: 15986076
[TBL] [Abstract][Full Text] [Related]
10. Activation of the purine salvage pathway in mononuclear cells of cardiac recipients treated with mycophenolate mofetil.
Devyatko E; Zuckermann A; Bohdjalian A; Roedler S; Dunkler D; Grimm M; Weigel G
Transplantation; 2006 Jul; 82(1):113-8. PubMed ID: 16861950
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients.
Goldsmith D; Carrey EA; Edbury S; Smolenski RT; Jagodzinski P; Simmonds HA
Clin Sci (Lond); 2004 Jul; 107(1):63-8. PubMed ID: 14723604
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease.
Larkin G; Lightman S
Ophthalmology; 1999 Feb; 106(2):370-4. PubMed ID: 9951492
[TBL] [Abstract][Full Text] [Related]
13. Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation.
Bemer MJ; Risler LJ; Phillips BR; Wang J; Storer BE; Sandmaier BM; Duan H; Raccor BS; Boeckh MJ; McCune JS
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1544-52. PubMed ID: 24923537
[TBL] [Abstract][Full Text] [Related]
14. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5'-monophosphate dehydrogenase in whole blood and isolated mononuclear cells.
Albrecht W; Storck M; Pfetsch E; Martin W; Abendroth D
Ther Drug Monit; 2000 Jun; 22(3):283-94. PubMed ID: 10850395
[TBL] [Abstract][Full Text] [Related]
15. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF).
Allison AC; Eugui EM
Clin Transplant; 1996 Feb; 10(1 Pt 2):77-84. PubMed ID: 8680053
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological profiles of mycophenolate mofetil (CellCept), a new immunosuppressive agent].
Yashima Y; Ohgane T
Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):131-7. PubMed ID: 11233304
[TBL] [Abstract][Full Text] [Related]
17. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
18. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil.
Sanquer S; Breil M; Baron C; Dhamane D; Astier A; Lang P
Clin Pharmacol Ther; 1999 Jun; 65(6):640-8. PubMed ID: 10391669
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil treatment following renal transplantation decreases GTP concentrations in mononuclear leucocytes.
Jagodzinski P; Lizakowski S; Smolenski RT; Slominska EM; Goldsmith D; Simmonds HA; Rutkowski B
Clin Sci (Lond); 2004 Jul; 107(1):69-74. PubMed ID: 14723603
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of mycophenolate mofetil.
Ransom JT
Ther Drug Monit; 1995 Dec; 17(6):681-4. PubMed ID: 8588241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
